ProPhase Historical Financial Ratios
| PRPH Stock | USD 0.65 0.03 4.41% |
ProPhase Labs is promptly reporting on over 110 different financial statement accounts. To analyze all of these accounts together requires a lot of time and effort. However, using these accounts to derive some meaningful and actionable indicators such as Book Value Per Share of 1.9, Invested Capital of 0.0, Average Payables of 517.3 K or Stock Based Compensation To Revenue of 0.0837 will help investors to properly organize and evaluate ProPhase Labs financial condition quickly.
ProPhase |
About ProPhase Financial Ratios Analysis
ProPhase LabsFinancial ratios are relationships based on a company's financial information. They can serve as useful tools to evaluate ProPhase Labs investment potential. Financial ratio analysis can also be defined as the process of presenting financial ratios, which are mathematical indicators calculated by comparing key financial information appearing on ProPhase financial statements. Financial ratios are useful tools that help investors analyze and compare relationships between different pieces of financial information across ProPhase Labs history.
ProPhase Labs Financial Ratios Chart
Add Fundamental
Price To Sales Ratio
Price to Sales Ratio is figured by comparing ProPhase Labs stock price to its revenues. An advantage to using Price to Sales ratio is that it is based on ProPhase Labs sales, a figure that is much harder to manipulate than other ProPhase Labs multiples. Because sales tend to be more stable P/S ratio can be a good tool for screening cyclical companies fluctuating earnings patterns. A valuation ratio that compares a company's stock price to its revenues, calculated by dividing the company's market cap by its total sales or revenue over a 12-month period.Dividend Yield
Dividend Yield is ProPhase Labs dividend as a percentage of ProPhase Labs stock price. ProPhase Labs dividend yield is a measure of ProPhase Labs stock productivity, which can be interpreted as interest rate earned on an ProPhase Labs investment. A financial ratio that shows how much a company pays out in dividends each year relative to its stock price, calculated as annual dividends per share divided by price per share.Ptb Ratio
Price-to-Book ratio, a financial valuation metric used to compare a company's current market price to its book value. It provides insight into the value that market participants place on the company's equity relative to its net asset value.Capex To Depreciation
The ratio of a company's capital expenditures to its depreciation expenses, indicating how much the company is investing in physical assets relative to the aging of existing assets.Most ratios from ProPhase Labs' fundamentals are interrelated and interconnected. However, analyzing fundamentals ratios one by one will only give a small insight into ProPhase Labs current financial condition. On the other hand, looking into the entire matrix of fundamentals ratios, and analyzing their relationships over time can provide a more complete picture of the company financial strength now and in the future. Check out Your Equity Center to better understand how to build diversified portfolios, which includes a position in ProPhase Labs. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in american community survey. For more detail on how to invest in ProPhase Stock please use our How to Invest in ProPhase Labs guide.As of now, ProPhase Labs' EV To Sales is decreasing as compared to previous years. The ProPhase Labs' current Inventory Turnover is estimated to increase to 7.69, while Price To Sales Ratio is projected to decrease to 1.66.
| 2022 | 2023 | 2024 (projected) | Dividend Yield | 0.0613 | 0.0705 | 0.067 | Price To Sales Ratio | 1.24 | 1.75 | 1.66 |
ProPhase Labs fundamentals Correlations
Click cells to compare fundamentals
ProPhase Labs Account Relationship Matchups
High Positive Relationship
High Negative Relationship
ProPhase Labs fundamentals Accounts
| 2019 | 2020 | 2021 | 2022 | 2023 | 2024 (projected) | ||
| Price To Sales Ratio | 2.31 | 7.33 | 1.38 | 1.24 | 1.75 | 1.66 | |
| Ptb Ratio | 2.03 | 10.08 | 1.86 | 2.4 | 1.57 | 1.5 | |
| Days Sales Outstanding | 252.13 | 79.34 | 174.13 | 110.27 | 298.63 | 313.56 | |
| Book Value Per Share | 0.97 | 0.91 | 3.86 | 4.02 | 2.87 | 1.9 | |
| Free Cash Flow Yield | (0.0469) | (0.0402) | (0.16) | 0.16 | (0.19) | (0.18) | |
| Stock Based Compensation To Revenue | 0.0753 | 0.1 | 0.0403 | 0.0325 | 0.0797 | 0.0837 | |
| Capex To Depreciation | 0.57 | 3.69 | 1.19 | 0.77 | 0.47 | 0.88 | |
| Pb Ratio | 2.03 | 10.08 | 1.86 | 2.4 | 1.57 | 1.5 | |
| Ev To Sales | 2.26 | 7.88 | 1.46 | 1.23 | 2.2 | 3.53 | |
| Free Cash Flow Per Share | (0.0924) | (0.37) | (1.18) | 1.55 | (0.84) | (0.8) | |
| Roic | (0.28) | (0.2) | 0.17 | 0.29 | (0.27) | (0.25) | |
| Inventory Turnover | 4.98 | 3.26 | 10.05 | 13.08 | 7.33 | 7.69 | |
| Net Income Per Share | (0.26) | (0.21) | 0.41 | 1.17 | (0.98) | (0.93) | |
| Days Of Inventory On Hand | 73.34 | 111.95 | 36.32 | 27.91 | 49.81 | 47.32 | |
| Payables Turnover | 16.81 | 2.63 | 6.58 | 8.8 | 3.0 | 2.85 | |
| Sales General And Administrative To Revenue | 0.45 | 0.46 | 0.28 | 0.38 | 0.78 | 0.82 | |
| Research And Ddevelopement To Revenue | 0.0336 | 0.0436 | 0.006579 | 0.005316 | 0.0319 | 0.0304 | |
| Capex To Revenue | 0.0231 | 0.12 | 0.0535 | 0.032 | 0.0711 | 0.0746 | |
| Cash Per Share | 0.12 | 0.73 | 1.14 | 1.1 | 0.28 | 0.26 | |
| Pocfratio | (27.09) | (41.07) | (7.99) | 5.34 | (6.85) | (7.2) | |
| Capex To Operating Cash Flow | (0.27) | (0.65) | (0.31) | 0.14 | (0.28) | (0.26) | |
| Pfcf Ratio | (21.31) | (24.86) | (6.09) | 6.19 | (5.36) | (5.63) | |
| Days Payables Outstanding | 21.72 | 138.92 | 55.47 | 41.45 | 121.68 | 127.77 | |
| Roe | (0.27) | (0.23) | 0.11 | 0.29 | (0.34) | (0.32) | |
| Ev To Operating Cash Flow | (26.57) | (44.12) | (8.46) | 5.27 | (8.6) | (9.03) | |
| Pe Ratio | (7.56) | (43.98) | 17.34 | 8.26 | (4.63) | (4.4) | |
| Return On Tangible Assets | (0.25) | (0.0827) | 0.0862 | 0.25 | (0.23) | (0.21) | |
| Ev To Free Cash Flow | (20.9) | (26.71) | (6.46) | 6.11 | (6.73) | (7.06) | |
| Earnings Yield | (0.13) | (0.0227) | 0.0577 | 0.12 | (0.22) | (0.2) | |
| Net Debt To E B I T D A | 1.24 | 0.16 | (5.31) | (0.0748) | (1.33) | (1.4) | |
| Current Ratio | 10.66 | 2.52 | 3.95 | 3.78 | 2.28 | 3.83 | |
| Tangible Book Value Per Share | 0.97 | 0.73 | 2.77 | 3.12 | 1.85 | 1.73 |
Currently Active Assets on Macroaxis
When determining whether ProPhase Labs offers a strong return on investment in its stock, a comprehensive analysis is essential. The process typically begins with a thorough review of ProPhase Labs' financial statements, including income statements, balance sheets, and cash flow statements, to assess its financial health. Key financial ratios are used to gauge profitability, efficiency, and growth potential of Prophase Labs Stock. Outlined below are crucial reports that will aid in making a well-informed decision on Prophase Labs Stock:Check out Your Equity Center to better understand how to build diversified portfolios, which includes a position in ProPhase Labs. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in american community survey. For more detail on how to invest in ProPhase Stock please use our How to Invest in ProPhase Labs guide.You can also try the Portfolio Dashboard module to portfolio dashboard that provides centralized access to all your investments.
Is Pharmaceuticals space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of ProPhase Labs. If investors know ProPhase will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about ProPhase Labs listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Quarterly Earnings Growth (0.95) | Earnings Share (1.53) | Revenue Per Share 0.996 | Quarterly Revenue Growth (0.81) | Return On Assets (0.23) |
The market value of ProPhase Labs is measured differently than its book value, which is the value of ProPhase that is recorded on the company's balance sheet. Investors also form their own opinion of ProPhase Labs' value that differs from its market value or its book value, called intrinsic value, which is ProPhase Labs' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because ProPhase Labs' market value can be influenced by many factors that don't directly affect ProPhase Labs' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between ProPhase Labs' value and its price as these two are different measures arrived at by different means. Investors typically determine if ProPhase Labs is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, ProPhase Labs' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.